HéMaVie, an innovative support solution for patients suffering from multiple myeloma

Improve the daily lives of patients

Multiple myeloma is a rare cancer of the bone marrow. Each year, about 5000 new cases of myeloma are detected in France. The average patient is 72-years old when diagnosed. The disease, along with its heavy treatments (chemotherapies, targeted therapies, autografts) lead to significant changes in everyday life: impact on social and family life, loss of autonomy; and impact on the quality of life (pain, anxiety, side effects). It is essential to support each patient in a reinforced and personalized manner, and to provide them with accurate and reliable information on the disease, its cause, and its progression.

A human and personalized engagement and support solution

The AF3M (French patient organization supporting patients with multiple myeloma) and Bristol Myers Squibb, a pharmaceutical company, joined forces along a common objective: to contribute to the improvement of the multiple myeloma care pathway and the patient experience. They called on Observia’s expertise to develop an innovative and personalized support solution called HéMaVie. HéMaVie aims to improve the lives of patients and to facilitate communication between healthcare professionals, patients, relatives, and caregivers. Via a multi-device, digital platform and a nurse coordinator, many services and tools are available night and day. HéMaVie is among the first ever human and concrete patient solution, strongly integrated into the patient journey.

Below are some examples of available services:

• Personalized coaching & nurse call support
• Social network and regional event directory
• Customized tool box & information guides

Get all details of the features in the full Success Story: